NYSE:RMD
RESMED INC
Global leader in sleep apnea treatment devices delivering consistent revenue growth and expanding margins through high-margin digital health solutions.
Key Metrics
Investment Thesis
Bull Case
Investors should consider ResMed as a high-quality compounder benefiting from an aging global population and rising prevalence of sleep disorders that drives secular demand for their devices. The company's expanding digital health portfolio offers multiple avenues for margin expansion beyond traditional hardware sales, supported by a balance sheet with $1.21B in cash providing ample flexibility for strategic acquisitions.
Bear Case
Concerns exist regarding potential market saturation in developed regions where sleep apnea prevalence is already high, which could limit future organic growth rates unless new indications are successfully commercialized. Currency fluctuations and geopolitical tensions in key markets like China could erode overseas earnings, while reliance on third-party distributors introduces channel margin compression risks.
About RESMED INC
ResMed Inc. designs and manufactures digital respiratory therapy devices used to treat sleep disorders like sleep apnea, primarily serving the global home healthcare market through its flagship AutoSet family of machines and CPAP equipment. The company operates in over 100 countries with a strong focus on innovation in digital health technologies that monitor and manage patient outcomes remotely. ResMed maintains a dominant position in the sleep therapy sector by combining hardware manufacturing with data analytics to improve long-term patient adherence and clinical efficacy.
Analysis
Management Discussion
ResMed delivered robust financial performance with revenue reaching $5.15B and net profit of $1.40B, reflecting a 9% year-over-year growth trajectory driven by strong demand for sleep apnea treatments. Operating cash flow surged to $1.75B, significantly exceeding net income due to non-cash adjustments and working capital efficiencies, while the company returned substantial value to shareholders through $300M in buybacks and $310.9M in dividends.
Industry Overview
The global respiratory therapy market is expanding rapidly due to increasing obesity rates and aging demographics that correlate directly with higher incidence of obstructive sleep apnea. Regulatory bodies worldwide are tightening standards for digital health devices, creating barriers to entry for new players while favoring established incumbents like ResMed with robust compliance frameworks.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $4.22B | $4.69B | $5.15B |
| Cost of Revenue | $1.87B | $2.03B | $2.09B |
| Gross Profit | $2.36B | $2.66B | $3.05B |
| Operating Expenses | $1.22B | $1.34B | $1.37B |
| Operating Income | $1.13B | $1.32B | $1.69B |
| R&D | $287.6M | $307.5M | $331.3M |
| G&A | $874.0M | $917.1M | $991.0M |
| Stock-Based Comp | $71.1M | $80.2M | $91.7M |
| D&A | $165.2M | $176.9M | $198.5M |
| Depreciation | $84.7M | $88.9M | $111.8M |
| Amortization | $30.4M | $33.0M | $32.1M |
| Other OpEx | $62.1M | $110.7M | $47.3M |
| Non-Operating Income | $-30.2M | $-55.1M | $-7.8M |
| Pre-Tax Income | $1.10B | $1.26B | $1.68B |
| Income Tax | $204.1M | $243.8M | $276.8M |
| Continuing Ops | $897.6M | $1.02B | $1.40B |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $897.6M | $1.02B | $1.40B |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $897.6M | $1.02B | $1.40B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $2.37B | $2.36B | $3.51B |
| Cash & Equivalents | $227.9M | $238.4M | $1.21B |
| Accounts Receivable | $704.9M | $837.3M | $939.5M |
| Inventory | $998.0M | $822.2M | $927.7M |
| Prepaid Expenses | $437.0M | $459.8M | $429.0M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $4.38B | $4.51B | $4.67B |
| PP&E (Net) | $537.9M | $548.0M | $550.8M |
| Goodwill | $2.77B | $2.84B | $3.05B |
| Operating Leases | $128.0M | $151.1M | $167.5M |
| Other LT Assets | $882.4M | $908.0M | $827.6M |
| Total Assets | $6.75B | $6.87B | $8.17B |
| Current Liabilities | $758.5M | $910.7M | $1.02B |
| Accounts Payable | $150.8M | $237.7M | $278.2M |
| Current Leases | $21.9M | $25.3M | $30.5M |
| Deferred Revenue | $138.1M | $152.6M | $166.0M |
| Taxes Payable | $72.2M | $107.5M | $132.3M |
| Other Current Liab | $9.9M | $9.9M | $9.9M |
| Long-Term Liabilities | $1.86B | $1.10B | $1.19B |
| LT Operating Leases | $116.9M | $141.4M | $153.0M |
| Other LT Liab | $1.59B | $818.9M | $877.6M |
| Total Liabilities | $2.62B | $2.01B | $2.21B |
| Shareholders' Equity | $4.13B | $4.86B | $5.97B |
| Retained Earnings | $4.25B | $4.99B | $6.08B |
| AOCI | $-272.5M | $-251.5M | $-74.7M |
| Total L&E | $6.75B | $6.87B | $8.17B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $897.6M | $1.02B | $1.40B |
| Non-Cash Adjustments | $-729.1M | $180.9M | $185.7M |
| Working Capital Changes | $524.8M | $199.4M | $165.2M |
| Cash from Operations | $693.3M | $1.40B | $1.75B |
| Capital Expenditures | $119.7M | $99.5M | $89.9M |
| Cash from Investing | $-1.16B | $-269.8M | $-200.0M |
| Debt Issuances | $1.07B | $105.0M | $0 |
| Debt Repayments | $405.0M | $835.0M | $40.0M |
| Share Buybacks | — | $150.0M | $300.0M |
| Dividends Paid | $258.3M | $282.3M | $310.9M |
| Cash from Financing | $422.9M | $-1.12B | $-606.3M |
| FX Effect | $-2.1M | $-1.7M | $25.8M |
| Net Change in Cash | $-45.8M | $10.5M | $971.1M |
| Beginning Cash | $273.7M | $227.9M | $238.4M |
| Ending Cash | $227.9M | $238.4M | $1.21B |
Frequently Asked Questions
How does RESMED INC make money?
Revenue is driven primarily by respiratory therapy devices including CPAP, APAP, and BiPAP machines which serve the core home care market, complemented by growth in digital monitoring systems that track patient data over time. The company also generates significant income from consumables and accessories required for device maintenance and patient comfort, creating a recurring revenue stream with high retention rates.
What are the main risks for RMD?
Regulatory hurdles in emerging markets could delay product approvals or increase compliance costs for digital health features. Supply chain disruptions affecting microchip availability or raw material sourcing could impact production capacity and margin expansion. Intense competition from larger medical device conglomerates may pressure pricing power over time.
What is RMD's competitive advantage?
ResMed possesses deep clinical expertise allowing it to tailor devices for specific respiratory conditions, while its proprietary software platform creates a sticky ecosystem that ensures long-term customer retention. The company's global distribution network reaches remote markets effectively, and its continuous R&D investment in AI-driven diagnostics maintains a technological moat against smaller competitors.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.